Janus Henderson Group PLC Cytom X Therapeutics, Inc. Transaction History
Janus Henderson Group PLC
- $182 Billion
- Q2 2024
A detailed history of Janus Henderson Group PLC transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 6,301,983 shares of CTMX stock, worth $7.75 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,301,983Holding current value
$7.75 Million% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding CTMX
# of Institutions
76Shares Held
50.2MCall Options Held
22.3KPut Options Held
22.9K-
Tang Capital Management LLC San Diego, CA7.79MShares$9.58 Million1.16% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$6.43 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.89MShares$6.02 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3MShares$3.69 Million0.01% of portfolio
-
Acadian Asset Management LLC Boston, MA2.73MShares$3.36 Million0.01% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $81.1M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...